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Leukocytosis is occasionally seen in patients with presumptive but undiagnosed myeloproliferative 
disorders (MPD).  A 74-year-old woman was admitted to our hospital for tarry stools,  anemia,  and 
marked peripheral leukocytosis of 1.4×105/µL.  Gastroenteroscopy revealed an acute gastric and 
duodenal mucosal lesion that was treated successfully via endoscopic hemoclipping.  Bone marrow 
aspiration revealed marked megakaryocyte proliferation with atypia of naked nuclei and marrow 
hypercellularity (90ｵ cellularity).  A ﬂuorescence in situ hybridization test could not detect the BCR-
ABL fusion gene.  Bone marrow aspiration later revealed further abnormalities of megakaryocytes.  
The patient died from cerebral bleeding.  The present case fulﬁlled 2 of the 3 major criteria of pri-
mary myeloﬁbrosis according to the World Health Organization 2008 classiﬁcation: namely,  mega-
karyocytic hyperplasia with hypercellular marrow and granulocytic hyperplasia.  However,  the 
megakaryocytic abnormality was not strictly compatible with the criteria.  Instead,  we considered 
preﬁbrotic primary myeloﬁbrosis as a possibility,  although myelodysplastic syndrome/myeloprolifer-
ative neoplasm,  unclassiﬁable (MDS/MPN-U) was technically the correct diagnosis.  The present case 
shows that MPN diagnosis remains diﬃcult and suggests that other cases of peripheral leukocytosis 
with diagnosed MDS/MPN-U might include similar ﬁndings.
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eukocytosis in excess of 50,000cells/µL can be 
caused by acute leukemia,  chronic myeloprolif-
erative neoplasms (MPN) including chronic myeloid 
leukemia (CML),  essential thrombocythemia (ET),  
primary myeloﬁbrosis (PMF),  or polycythemia vera 
(PV) [1-4].  Other causes of leukocytosis include 
leukemoid reactions consequent to tuberculosis and 
other severe infections,  adverse drug eﬀects or,  on 
rare occasion,  granulocyte colony-stimulating factor 
(G-CSF)-producing tumors [5].
　 MPN diagnosis [6-10] occasionally proves to be 
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diﬃcult and has remained a matter of debate since 
William Dameshek ﬁrst classiﬁed PV,  ET,  and PMF 
as pathogenetically related myeloproliferative disor-
ders (MPD) in 1951 [11].  Leukocytosis is occasion-
ally observed in patients with presumptive but undiag-
nosed MPN [12].
　 We report herein a case of a patient admitted with 
severe peripheral leukocytosis (140,000cells/µL);  
this case appeared to fulﬁll the criteria of preﬁbrotic 
PMF and could have been considered PMF,  although 
myelodysplastic syndrome/myeloproliferative neoplasm,  
unclassiﬁable (MDS/MPN-U) was technically the cor-
rect diagnosis.
Case Presentation
　 A 74-year-old woman was referred to the oﬃce of 
a physician of internal medicine because of tarry 
stools in December,  2009.  Complete blood count 
(CBC) revealed anemia and a markedly elevated white 
blood cell (WBC) count of 1.4×105/µL.  The patient 
was referred to us for consultation and was admitted 
the following day to Himeji St. Mary hospital.  Since 
October 2009,  she had been using a Chinese medical 
agent synthesized primarily from aged garlic extract 
to improve her health,  but stopped taking this supple-
ment three days prior to her admission.  She also had 
a history of hypertension and hyperlipidemia but no 
history of smoking.  Her CBC results were almost 
normal in June,  2009,  which was 6 months before her 
admission (WBC count,  8,900/µL; red blood cell 
[RBC] count,  4.24×106/µL; hemoglobin [Hb] level,  
11.0 g/dL; and platelet [Plt] count,  1.77×105/µL).
　 At admission,  her WBC count was 124,000/µL,  
comprising 2ｵ promyelocytes,  5ｵ myelocytes,  1ｵ 
metamyelocytes,  83.5ｵ polymorphonuclear neutro-
phils,  4ｵ lymphocytes,  0ｵ eosinophils,  and 1.5ｵ 
basophils.  The following values were also recorded:  
RBC count,  1.64×106/µL; Hb,  4.3 g/dL; mean 
corpuscular volume,  84.1 fL; mean corpuscular Hb,  
26.2 pg; mean corpuscular Hb concentration,  31.2ｵ;  
and Plt,  1.46×105/µL.  Her serum lactate dehydro-
genase (LDH) level was 299 IU/L (normal range,  
105-210 IU/L).  A physical examination revealed 
conjunctival anemia and a non-palpable spleen;  
moreover,  no lymphadenopathy or skin eruptions were 
observed.  Gastroenteroscopy revealed an acute gas-
tric mucosal lesion (AGML) and an acute duodenal 
mucosal lesion (ADML; Fig.  1).  The patient received 
a blood transfusion,  and her gastric ulcer was treated 
successfully by endoscopic hemoclipping.
　 Bone marrow (BM) aspiration stained according to 
the May-Grunwald-Giemsa (Fig.  2A) and hematoxylin-
eosin protocols (Fig.  2B) revealed a nucleated cell 
count of 611×103/µL (normal range,  50-200×103/
µL),  a megakaryocyte count of 712/µL (normal range,  
50-150/µL),  and a myeloid to erythroid cell ratio of 
9.5 (normal range,  1.5-3.3),  indicating marked myel-
oid cell proliferation.  However,  there were no ﬁnd-
ings compatible with acute leukemia (Table 1).  A sil-
ver-stained BM biopsy specimen revealed no BM 
ﬁbrosis (Fig.  2C).  The megakaryocytes displayed 
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Fig. 1　 Gastrointestinal scope showing an acute gastric mucosal 
lesion (A) and acute duodenal mucosal lesion (B).
atypia (Fig.  3A and B).  A BM biopsy revealed marked 
marrow hypercellularity (90ｵ cellularity).  No obvious 
ﬁbrosis was observed.  Moreover,  ﬂuorescence in situ 
hybridization (FISH) did not indicate the presence of 
the BCR-ABL fusion gene.  In addition,  an elevated 
neutrophil alkaline phosphatase (NAP) score of 426 
was observed (normal range,  188-367).  The lack of 
the BCR-ABL fusion gene and the elevated NAP score 
were inconsistent with the chronic phase of chronic 
myeloid leukemia,  during which the NAP score would 
normally decrease.  A cytogenetic analysis of 20 cells 
revealed a normal karyotype (46,  XY) in 18 cells and 
a 46,  XX,  del (20) (q1?) in 2 cells.  These ﬁndings did 
not support a diagnosis of PV or CML,  and the pres-
ence of BM megakaryocytic hyperplasia and hypercel-
lular marrow with granulocytic hyperplasia suggested 
preﬁbrotic PMF.
　 The Chinese drugs that the patient had used previ-
ously were synthesized mostly from aged garlic 
extract.  A drug-induced lymphocyte stimulation test 
(DLST) was conducted because we suspected that 
these drugs might have induced the marked leukocyto-
sis.  Following the incubation,  the numbers of lympho-
cytes treated with and without (control) the Chinese 
drug were 104 and 152 counts per minute,  respec-
tively,  suggesting that the drug did not stimulate 
lymphocyte proliferation and presumably had not 
caused the leukocytosis.
　 Following admission,  the patientʼs WBC count 
remained markedly high at 30,000-60,000/µL.  Her 
serum G-CSF level was 19.5 pg/mL (normal,  ＜39 
pg/mL),  which excluded the possibility of a G-CSF-
producing tumor.  Chest and abdominal computed 
tomography (CT) revealed no abnormalities indicative 
of a severe infection,  tumor,  or bone metastasis.  The 
splenic size was within the upper limit of the normal 
size range.  The patient was discharged from the 
hospital on day 27 and received no speciﬁc treatment 
for her leukocytosis.  Her ﬁnal visit to our hospital 
was in February,  2010.  On that date,  the CBC 
revealed a WBC count of 58,000/µL,  RBC count of 
4.15×106/µL,  Hb level of 10.9 g/dL,  Plt count of 
1.04×105/µL,  and LDH level of 299 IU/L.  The 
patient was followed-up at an outpatient clinic of the 
Himeji Red Cross hospital.  The BM aspirations (Fig.  
3C and E) and HE clots (Fig 3D,  F) performed in 
February 2010 (Fig.  3C,  D) and April 2011 (Fig.  
3E,  F) revealed megakaryocytic atypia.  A BM aspi-
ration revealed a nucleated cell count of 1.72×106/
µL (normal range,  50-200×103/µL),  and a myeloid 
to erythroid cell ratio of 15.8 (normal range,  1.5-3.3) 
in February 2010 (Table 1).  No JAK2 gene mutation 
was found,  contrary to usual ﬁndings in PV.  The 
MPL mutation (W515K/L) was not examined.  The 
patient was prescribed a daily hydroxycarbamide dose 




Fig. 2　 A,  Light microscopic ﬁndings of a bone marrow (BM) 
smear stained by May-Grunwald-Giemsa. Low-power ﬁeld; B,  HE.  
Bone marrow aspiration showed marked proliferation of myeloid 
cells.  High-power ﬁeld; C,  Silver stain of BM biopsy specimen 
showing no ﬁbrosis of BM.  Low-power ﬁeld.
of 500 mg because her peripheral WBC count was 
recorded as ＞100,000/µL in June,  2011.  The WBC 
count subsequently increased to 210,000/µL in 
August,  2011.  The patient died the following day from 
multiple cerebral hemorrhages; this occurred pre-
cisely 1 year and 10 months after the ﬁrst admission.
Discussion
　 For decades,  the classiﬁcation of BCR-ABL-negative 
MPN has remained a matter of debate.  The World 
Health Organization (WHO) 2008 classiﬁcation dis-
criminated between ET,  PMF,  and PV [13-15].  
Histopathology is the key component of such diagnoses 
and is deﬁned by megakaryocyte proliferation atypia 
even in the absence of overt ﬁbrosis; this technique 
also facilitates the diﬀerential diagnosis of MPN dis-
orders and myelodysplastic syndromes [16].
　 In some percentage of PMF cases,  ﬁbrosis might 
exhibit a non-ﬁbrotic cellular phase.  This prolifera-
tion is clonal in nature [17,  18].  The present case 
fulﬁlled 2 of the 3 major criteria of PMF,  speciﬁ-
cally the presence of hypercellular marrow with 
granulocytic hyperplasia; however,  these ﬁndings did 
not meet the criteria of PV,  CML,  MDS,  or other 
myeloid neoplasms and secondary causes of ﬁbrosis 
were excluded.  The present case exhibited abnormal 
megakaryocytic hyperplasia,  but the ﬁndings were not 
strictly compatible with preﬁbrotic MF,  which would 
include small- to large-sized megakaryocytes with an 
aberrant nuclear/cytoplasmic ratio,  hyperchromatic,  
bulbous,  or irregularly folded nuclei,  dense cluster-
ing,  an increased nucleo-cytoplasmic ratio,  and the 
presence of cloudlike nuclei,  hyperchromatic-dysplas-
tic nuclei,  paratrabecular megakaryocytes,  or tight 
clusters [19,  20].  The present case fulﬁlled 2 of the 
4 minor criteria required for diagnosis,  speciﬁcally 
the presence of anemia and increased serum LDH.  
Anemia on admission might be inﬂuenced by alimen-
tary tract bleeding; however,  3 months after admis-
sion,  Hb was 10.9 g/dl,  which can be considered to be 
anemic.  Two minor criteria,  namely splenomegaly and 
leukoerythroblastosis,  were not observed.  Based on 
these ﬁndings,  we could not conﬁrm a diagnosis of 
preﬁbrotic PMF.  In addition,  thrombocythemia,  which 
is usually present in PMF,  was not observed in the 
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Table 1　 Marrow diﬀerential cell count
Date 2009 Dec 2010 Feb
Group Cell type Fraction Fraction Referencerange (%)
Cells of myelopoiesis
Myeloblasts 3.0% 2.4% 0.2-2.9
Promyelocytes 7.6% 1.5% 1.5-8.4
Myelocytes 16.8% 32.5% 1.0-9.7
Metamyelocytes 14.4% 32.5% 3.6-14.6
Band cells 16.8% 8.5% 10.6-24.6
Segmented neutrophils 26.2% 28.2% 8.5-33.2
Eosinophils 2.6% 2.7% 1.2-5.3
Basophils 1.6% 0.0% 0-0.8
Total 89.0% 91.9% 50.4-70.5
Cells of erythropoiesis
Proerythroblasts 0.2% 0.3% 0.2-1.3
Basophilic erythroblasts 1.2% 0.9% 0.8-6.7
Polychromatic erythroblasts 6.8% 3.2% 4.1-29.1
Orthochromatic erythroblast 1.2% 1.4% 0.1-5.7
Total 9.4% 5.8% 18.4-33.8
Other cell types
Megakaryocytes 0.4% 0.0% 0-0.1
Plasma cells 0.2% 0.1% 0.2-1.7
Lymphocytes 1.0% 1.9% 5.0-32.6
Monocytes 0% 0.6% 0.7-6.0
present case.  The patient was diagnosed with myelo-
dysplastic syndrome/myeloproliferative neoplasm,  
unclassiﬁable (MDS/MPN-U) [21]; however,  the case 
could be made for a diagnosis of preﬁbrotic PMF.
　 The AGML,  ADML,  and gastric ulcer present at 
admission occurred when the patient had a peripheral 
WBC count of 140,000/µL,  and the fatal cerebral 
hemorrhages occurred when the WBC count was 
210,000/µL.  Both of these conditions were assumed 
consequent to a bleeding tendency that is sometimes 
observed in patients with MPN.  An elevated leukocyte 
count is correlated with an increased risk of total 
thrombosis and,  in particular,  an increased risk of 
arterial thrombosis [22].  If preﬁbrotic PMF cases 
could be diagnosed early among MDS/MPN-U cases,  
it would help to reveal characteristics of relatively 
rare preﬁbrotic PMF.
　 Initially,  our putative diagnosis was preﬁbrotic 
PMF,  but the present case did not exhibit a mega-
karyocytic abnormality that would have been strictly 
compatible with preﬁbrotic PMF.  The present case 
demonstrated that MPN diagnoses remain diﬃcult and 
that several cases of severe peripheral leukocytosis 
and anemia [23],  in which the patients died following 
diagnoses of MDS/MPN-U,  might have included 
similar ﬁndings.
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Fig. 3　 Megakaryocytes showed atypia.  A,  B,  Megakaryocytes showed atypia of naked nuclei on admission in Dec 2009; C,  D,  The 
BM aspiration and HE clot in February 2010 showed atypia of megakaryocytes; E,  F,  The BM aspiration and HE clot in April 2011 
showed atypia of megakaryocytes.  A,  B,  C,  E,  and F are high-power ﬁelds.  D is a low-power ﬁeld.
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